You are here

Article Text

Article menu
Download PDFPDF
Editorial
Hypertension and consequent mortality risk in China
  1. Denes Stefler1,
  2. Leonardo Roever2
  1. 1 Department of Epidemiology and Public Health, University College London, London, UK
  2. 2 Department of Clinical Research, Federal University of Uberlândia, Uberlandia, Brazil
  1. Correspondence to Dr Denes Stefler, Department of Epidemiology and Public Health, University College London, London WC1E 6BT, UK; denes.stefler{at}ucl.ac.uk

http://dx.doi.org/10.1136/jech-2018-211430

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    High blood pressure is the leading cause of morbidity and mortality worldwide. In fact, according to the estimations by the Global Burden of Disease project, it was the most important risk factor among women and second among men in 2016, responsible for about 90 million and 122 million disability-adjusted life-years, respectively.1 In addition to being a major risk factor for coronary heart disease and stroke, as well as a key component of metabolic syndrome, it is often considered as a distinct illness on its own right.2 3

    Prevalence of hypertension in Asian countries, particularly in China, is especially high. It is estimated that in this country nearly half of the adult population between the ages of 35 and 75 years has high blood pressure, with only half of these individuals are aware of their condition, less than one-third are treated and less than 10% are treated adequately.4 Considering these striking …

    View Full Text

    Footnotes

    • Contributors All authors contributed equally and agreed to the editorial content.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles